Dose Dependent Reduction in Anti-dsDNA Antibody Levels Observed With Abetimus Sodium Through 52 Weeks in the Phase 3 ASPEN Study (Abetimus Sodium in Patients With a History of Lupus Nephritis)
M. Tansey, et al
Poster Session
American College of Rheumatology 2008
October 27, 2008
Direct Medical Cost of Renal Flare in Lupus Nephritis
K. Kalunian, et al
Poster Session
American College of Rheumatology 2008
October 27, 2008
Direct Medical Cost of Renal Flare in Lupus Nephritis
D. Ward, et al
Poster Session
American Society of Nephrology Renal Week
November 8, 2008
Interim Analysis Reveals Dose Dependent Reduction in Anti-dsDNA Antibody Levels With Abetimus Sodium Through 52 Weeks in the Phase 3 ASPEN Study (Abetimus Sodium in Patients With a History of Lupus Nephritis)
M. Tansey, et al
Poster Session
American Society of Nephrology Renal Week
November 8, 2008
PHARMACOKINETICS OF HIGH DOSE ABETIMUS SODIUM IN NORMAL SUBJECTS WITH SPECIFIC ASSESSMENT OF EFFECT ON COAGULATION
M. Linnik, et al
Poster Session
Annual European Congress of Rheumatology “EULAR 2008”
Paris, France
June 12, 2008
TRADITIONAL AND POPULATION PHARMACOKINETICS OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH A HISTORY OF RENAL DISEASE
M. Linnik, et al
Poster Session
Annual European Congress of Rheumatology “EULAR 2008”
Paris, France
June 12, 2008
Abetimus Sodium as Maintenance Therapy for Lupus Nephritis: Protocol Overview and Progress Update for the Phase 3 ASPEN Study
M. Tansey, et al
Poster Session
7th European Lupus Meeting
Amsterdam, The Netherlands
May 7, 2008
|
Pharmacokinetics of High-Dose Abetimus Sodium in Normal Subjects With Specific Assessment of Effect on Coagulation
M. Linnik, et al
Published in the Journal of Clinical Pharmacology
2008
Volume 48:pp. 909-918
Abetimus Sodium for Renal Flare in Systemic Lupus Erythematosus
Results of a Randomized, Controlled Phase III Trial
MH Cardiel, et al
Published in Arthritis & Rheumatism
August 2008
Volume 58, No. 8, pp. 2470-2480
|